<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257269</url>
  </required_header>
  <id_info>
    <org_study_id>031/06</org_study_id>
    <nct_id>NCT01257269</nct_id>
  </id_info>
  <brief_title>Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)</brief_title>
  <acronym>TTP registry</acronym>
  <official_title>Thrombotic Thrombocytopenic Purpura Registry - A Prospective Observational Study for Patients Suffering From Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mach Gaensslen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxalta Innovations GmbH, Wien, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder&#xD;
      characterized by thrombocytopenia as a result of platelet consumption, microangiopathic&#xD;
      hemolytic anemia, occlusion of the microvasculature with von Willebrand&#xD;
      factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a&#xD;
      severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1&#xD;
      motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13&#xD;
      gene mutations.&#xD;
&#xD;
      Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman&#xD;
      syndrome patients varies considerably without an apparent genotype-phenotype correlation. In&#xD;
      2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family&#xD;
      members to identify possible triggers of acute bouts of TTP, to document individual clinical&#xD;
      courses and treatment requirements as well as possible side effects of long standing plasma&#xD;
      substitution, e.g. alloantibody formation or viral infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Thrombocytopenia and microangiopathic hemolytic anemia together with a severely deficient&#xD;
      ADAMTS13 activity confirm the diagnosis of acute thrombotic thrombocytopenic purpura (TTP).&#xD;
      Today two forms of classical TTP are distinguished. The acquired form is caused by&#xD;
      circulating auto-antibodies, mainly Immunoglobulin G (IgG), inhibiting ADAMTS13 (a&#xD;
      disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) activity. In&#xD;
      contrast, hereditary TTP, also known as Upshaw-Schulman syndrome (USS); #274150 Online&#xD;
      Mendelian Inheritance in Man (OMIM), is the result of severe constitutional deficiency of&#xD;
      ADAMTS13 due to compound heterozygous or homozygous mutations in the ADAMTS13 gene.&#xD;
&#xD;
      The clinical course of USS is variable with rather mild courses in some of the patients&#xD;
      requiring plasma infusions only in special situations (i.e. pregnancy), while in others&#xD;
      severe courses with important sequelae and even death in early childhood occur. The reasons&#xD;
      for the variable clinical presentation and treatment requirements have not been elucidated.&#xD;
      It seems likely, that additional, hitherto unidentified factors besides severe ADAMTS13&#xD;
      deficiency modify the clinical course.&#xD;
&#xD;
      At present, the clinical symptoms and laboratory values on which to base treatment regimens&#xD;
      for hereditary TTP are poorly understood. Furthermore, increasing awareness of hereditary TTP&#xD;
      results in rising numbers of patients in need of treatment and/or prophylaxis. However,&#xD;
      currently very little is known on side effects of long standing plasma substitution.&#xD;
      Alloimmunization with the formation of antibodies acting as inhibitors of treatment are well&#xD;
      known in other congenital coagulation factor deficiencies (e.g. hemophilia A), but so far no&#xD;
      case of treated hereditary TTP with subsequent antibody formation has been reported. It is&#xD;
      the aim of the hereditary TTP Registry to provide information on the clinical course of the&#xD;
      disease in as many patients as possible and therefore help to establish recommendations on&#xD;
      the necessity, modalities, and risks of prophylactic plasma therapy in patients with&#xD;
      hereditary TTP. Furthermore, it will help to gain detailed insight into triggers and risk&#xD;
      factors of acute bouts of TTP.&#xD;
&#xD;
      Moreover, the hereditary TTP Registry will provide information for family members on their&#xD;
      risk to develop TTP-like or TTP-related disorders.&#xD;
&#xD;
      Objective&#xD;
&#xD;
      Primary objective: Collection of as much information as possible on the clinical&#xD;
      presentation, disease course, disease-modifying factors, and treatment modalities of patients&#xD;
      suffering from hereditary thrombotic thrombocytopenic purpura (TTP).&#xD;
&#xD;
      Secondary objective: To document potential adversary effects of (long-term) plasma treatment&#xD;
      in patients with hereditary thrombotic thrombocytopenic purpura (TTP).&#xD;
&#xD;
      Methods&#xD;
&#xD;
      The TTP Registry is designed to collect both retrospective and prospective clinical,&#xD;
      molecular, and observational data on patients with confirmed or suspected hereditary TTP.&#xD;
      Additionally, the Registry will collect data from family members of TTP patients enrolled in&#xD;
      the Registry. The Registry will enroll as many confirmed or suspected hereditary TTP patients&#xD;
      and their family members as possible; there is no cap on enrollment. The Registry enrollment&#xD;
      and follow-up periods are open-ended. The endpoints for patients with confirmed or suspected&#xD;
      hereditary TTP and family members are death or withdrawal of consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical presentation and disease course in hereditary TTP</measure>
    <time_frame>every year until death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of disease-modifying factors, including genotype-phenotype correlation</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment requirements in hereditary TTP patients</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of potential adversary effects of (long-term) plasma treatment</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of hereditary TTP</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical course in family members</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Congenital Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Familial Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Thrombotic Thrombocytopenic Purpura, Congenital</condition>
  <condition>Upshaw-Schulman Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Family members of patients with confirmed hereditary TTP</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>No interventions planned: treatment of patients at the discretion of the treating/responsible physician</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with either confirmed or with suspected hereditary TTP and their family members&#xD;
        are eligible for enrollment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe ADAMTS13 deficiency ( ≤ 10% activity) and no ADAMTS 13 inhibitor on two or more&#xD;
             occasions at least one month apart&#xD;
&#xD;
          -  Being a family member of a confirmed or suspected patient&#xD;
&#xD;
          -  Molecular analysis of ADAMTS13 gene with one or more mutations and/or positive&#xD;
             infusion trial (full recovered ADAMTS13 activity after infused fresh frozen plasma&#xD;
             (FFP) with a plasma half-life of 2-4 days)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna A Kremer Hovinga, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernhard Lämmle, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center, Center for Thrombosis and Hemostasis, Mainz, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshihiro Fujimura, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Hrachovinova, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Hematology and Blood Transfusion, Coagulation Laboratory, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petter Quist-Paulsen, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology, St Olavs Hospital, 7006 Trondheim, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhard Schneppenheim, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James N. George, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oklahoma Health Sciences Center, Department of Medicine, United States of America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul N Knoebl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna, Div. Hematology and Hemostasis, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna A Kremer Hovinga, MD</last_name>
    <phone>+41 31 632 02 65</phone>
    <email>johanna.kremer@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erika Tarasco, Ph.D.</last_name>
    <phone>+41 31 632 56 90</phone>
    <email>erika.tarasco@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73126-0901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James N. George, M.D.</last_name>
      <phone>405-271-4222</phone>
      <email>james-george@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>James N. George, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Medicine 1, Div. Hematology and Hemostasis Waehringer Guertel 18-20</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul N. Knoebl, M.D.</last_name>
      <phone>+43 1 40400 4410</phone>
      <email>paul.knoebl@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Paul N. Knoebl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion, Coagulation Laboratory, U nemocnice 1</name>
      <address>
        <city>Prague 2</city>
        <zip>CZ-12820</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Hrachovinova, Ph.D.</last_name>
      <phone>+420 2 2197 271</phone>
      <email>Ingrid.Hrachovinova@uhkt.cz</email>
    </contact>
    <investigator>
      <last_name>Ingrid Hrachovinova, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Martinistr 52</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reinhard Schneppenheim, M.D., Ph.D.</last_name>
      <phone>+49 40 7410 54270</phone>
      <email>schneppenheim@uke.de</email>
    </contact>
    <investigator>
      <last_name>Reinhard Schneppenheim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nara Medical University, Department of Blood Transfusion Medicine, Shijyo-cho 840</name>
      <address>
        <city>Kashihara city</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshihiro Fujimura, M.D.</last_name>
      <phone>+81 744 22 3051</phone>
      <phone_ext>3289</phone_ext>
      <email>yoshifuji325@naramed-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshihiro Fujimura, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trondheim University St Olavs Hospital, Department of Hematology, PO Box 3250 Sluppen</name>
      <address>
        <city>Trondheim</city>
        <zip>NO-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Quist-Paulsen, M.D., Ph.D.</last_name>
      <phone>+47 815 55 850</phone>
      <email>Petter.Quist-Paulsen@stolav.no</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Sophie von Krogh, M.D.</last_name>
      <phone>+47 815 55 850</phone>
      <email>Anne-Sophie.von.Krogh@stolav.no</email>
    </contact_backup>
    <investigator>
      <last_name>Petter Quist-Paulsen, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie von Krogh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna A Kremer Hovinga, MD</last_name>
      <phone>+41 31 632 02 65</phone>
      <email>johanna.kremer@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Isabella Aebi, BMA</last_name>
      <phone>+41 31 632 77 16</phone>
      <email>isabella.aebi-huber@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Johanna A Kremer Hovinga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.ttpregistry.net</url>
    <description>Additional information</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombotic thrombocytopenic purpura</keyword>
  <keyword>ADAMTS13</keyword>
  <keyword>Von Willebrand factor</keyword>
  <keyword>Von Willebrand factor cleaving protease</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Hemolytic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

